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ABSTRACT
Recently it has been shown that several analogues of the clinically ineffective trans-DDP exhibit
antitumor activity comparable to that of cis-DDP. The present paper describes the binding of antitumor trans-
[PtCI2(E-iminoether)_,] (trqns-EE) to guanosinemonophosphate (GMP) and adenosinemonophosphate (AMP).
We have used HPLC and ’H and 15N NMR to characterize the different adducts. In the case of a 1" mixture
of trans-EE and GMP, at an early stage of the reaction, a monofunctional adduct is formed which,
subsequently, is partly converted into a monosolvated monofunctional species. After about 70 hours an
equilibrium is established between chloro and solvato monofunctional adducts at a ratio of 30/70. In the
presence of excess GMP (4:1) the initially formed monofunctional adducts react further to give two
bifunctional adducts, one with the iminoether ligands in their original E configurations and the other with the
iminoether ligands having one E and the other, Z configurations. The coordination geometry obtained by
energy minimization calculations is in qualitative agreement with 2D NMR data.
INTRODUCTION
The antitumor activity of cis-diamminedichloroplatinum(II) (cis-DDP), the most widely used metal-
based anticancer drug, has been associated with formation of adducts with DNA (for recent reviews see [1]).
Since the trans isomer of cis-DDP is clinically ineffective it was assumed that a structure-activity relationship
exists where only the cis geometry is therapeutically active. However, recently, it has been shown that several
analogues of trans-DDP exhibit antitumor activity comparable to that of cis-DDP [2-5]. Of particular interest
is a group of iminoether derivatives analogous to trans-DDP: e.g. trans-[PtCI,_(iminoether),_] which was
shown to be endowed with significant in vivo antitumor activity [3,6]. Surprisingly, these compounds were
remarkably more cytotoxic than their congener cis-[PtCI,_(iminoether),_] [2].
In addition to the c is and trans geometry, platinum-iminoether complexes can have either E or Z
configuration depending on the relative position of the alkoxy group and the N-bonded Pt with respect to the
C=N double bond, and this represents another aspect to be considered for the evaluation of structure-activity
relationships. The DNA binding mode of trans-EE in a cell free medium has been characterized by several
biophysical methods [7]. As a result of these studies it has been concluded that kinetically stable trans-EE
forms monofunctional adducts at guanine residues in double-helical DNA. As a consequence trans-EE is
assumed to modify DNA differently to clinically ineffective trans-DDP.
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The nature of the non-leaving groups, i.e. the amine ligands in trans-DDP and che iminoether ligands
in trans-EE, somehow play an important role and it has been speculated that in the latter case one of the drug
DNA interactions could not involve directly the metal ion but be mediated by the iminoether ligand. Such a
type of interaction with DNA would place the platinum-iminoether complex at the junctiot :betxveen’cis:DDP
and non-metallic cytotoxic agents.
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Recently, a detailed HPLC and NMR spectroscopic analysis of the DNA duplex consisting of trans-
EE platinated 5’-d(CCTCG*CTCTC) (IM) and its complement 5"-d(GAGAGCGAGG) (II) was described [8].
The analysis revealed that the binding pattern of trans-EE is more complex than first anticipated involving
pH and sequence-dependent isomerization reactions and deplatination when the NMR sample contains high
NaCI concentration (0.2 M). This paper describes a more detailed picture of the binding pattern between
trans-EE and mononucleotides (GMP and AMP).
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Figure I. Distribution curves for the trans-EE platination reaction of nucleotides at 1" molar ratio.
(a) GMP (.), (b) AMP. at pH 6.8 in H20, 298 K.
MATERIALS AND METHODS
Sample preparation.
The trans-EE complex was synthesized by the Bari group as previously described [9]. 5"-
riboguanosinemonophosphate (sodium salt) (GMP) and the corresponding adenine phosphate (AMP) were
purchased from Sigma and used without further purification. Deuterium oxide was purchased from
Flurochem Limited Company. The reactions between trans-EE and the mononucleotides were performed
using the PtCI2[E-HN=C(OMe)Me]. and the nucleotide in molar ratios 1:1 and 4:1, respectively, at pH 6.8.
The solutions were kept in the dark at room temperature. The platinated nucleotides were purified by HPLC
on a Waters 626 LC instrument using the Millenium 32 software [10]. A reverse phase Waters Symmetry C8
column was used with gradient eluent (0-50 % methanol) in 50 mM NaCIO4 at a flow rate of 0.8 ml/min. The
reactions were monitored by HPLC until the equilibrium was reached. The platinated samples for NMR
experiments were separated by HPLC, lyophilized and dissolved into 0.5 ml D20. No buffer was added and
the pH value of the solution was about 4. The samples of unplatinated GMP and AMP were dissolved in 0.5
ml D20, pH 5.5 (final concentration: 0.1 M).
NMR Spectroscopy.
NMR experiments were performed on a Bruker DRX 600 instrument, operating at 600 MHz for IH
NMR spectroscopy. D H NMR spectra were collected with a total of 32K complex points and 64 transients.
For all D and 2D spectra the spectral width were 7200 Hz and a relaxation delay of 2 s was used. The
presaturation pulse sequence was used for the samples in DzO and the 3-9-19 WATERGATE pulse sequence
was used for the samples in HzO solution for water suppression [11]. In the ROESY and NOESY
experiments, a total of 2048 complex points in t2 were collected for each of 256 ti increments and 80
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transients were averaged for each increment. Two-dimensional [H, SN] HMQC spectra with K complex
points along t2 were recorded for 128 transients. The experiment was optimized for two-bond IH-15N
connectivity involving nonexchangeable protons, where A 1/2JNH 48 ms. Couplin constants are found in
the range of 6-14 Hz, except for 2JN9.HV which is found to be 4.1 Hz in GMP. The IHSN spectra widths were
1929 and 6082 Hz for free GMP and 1912 and 12064 Hz for the trans-EE adduct, respectively. The FID’s
were multiplied by a square-cosine function and zero-filled to 2048 complex points along tl and t2. The NMR
data were processed on a Silicon Graphics INDY workstation using the program FELIX (Bio,sym) [12] and
on a 133 MHz Pentium PC using 1D and 2D WIN-NMR (Bruker) [13]. The one dimensional ’H FID’s were
multiplied by an exponential window function prior to Fourier transformation. Typically, 0.3 Hz was added
to the line widths. No baseline correction was needed. IH spectra were referenced to the HDO-resonance at
4.76 ppm at 298 K and SN spectra relative to saturated NHaCI solution at -352.9 ppm.
RESULTS
HPLC analysis
Small fractions of the 1" trans-EE/GMP reaction mixture were analyzed by HPLC at several time
intervals. The species distribution is given in Figure a. Initially, two species M1 and M2 are formed at
different rates, the faster forming species, M1, attains a maximum concentration after ca 10 hours and is then
partly converted to a second species, M2; at equilibrium the ratio M1/M2 is ca. 30:70. The reaction proceeds
with a half-time of 3.5 h (at 298 K, cat mM).
For the reaction with excess GMP (4:1) a more complex mixture of products was formed. Similarly to
the case of a 1"1 ratio of reactants, two monofunctional adducts M1 and M2 are formed initially and are then
converted into two bifunctional species (M3 and M4) which reach a concentration ratio of 5:1 after 20 days
and have chromatographic retention times of 34 and 33 min., respectively. For longer reaction time the
amount ofM4 increased further and after two months exceeded that ofM3.
For AMP the reaction is much slower than for GMP (Figure b). The half-time tl/2 23 h is estimated
from the HPLC trace. After about 7 days about 91% ofAMP has reacted. As for GMP two major species
M1(60%) and M2 (20%) are formed, a chloro and an aquacomplex, respectively. In addition, two minor
species (less than 5%) are formed, probably representing the corresponding chloro and aqua NI platinated
complexes.
5.0 4.0
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Figure 2. H NMR spectra for adduct M recorded at different time intervals, pH 4.8, in D20 at 298 K.
(a) newly prepared sample. (b) 20 hours later.
(b) (The peak at 3.4 ppm is the trace residue of methanol from HPLC eluent.)
NMR assignments
Monofunctional GMP adducts. The D H NMR spectra were recorded at different time intervals for the
reaction mixture and for the separate HPLC fractions. Figure 2 exhibits the D spectra for M recorded at
different time intervals. Integration of the D spectra confirms the 1:1 ratio ofGMP to trans-EE, (1:6 of H8
tO CH3 or CH30 peak). The NH proton of the iminoether ligands exchanges slowly with D20 during 2D
experiment at 298 K and disappear after about 20 hours. The proton chemical shifts of the resonance of the
different platinated species are listed in Table 1.
The G-H8 resonance for M and M2 are shifted 0.46 ppm and 0.40 ppm downfieid relative to
unplatinated GMP, respectively. Platinum coordination at N7 is usually found to produce H8 downfield shifts
in the 0.5 ppm range as a result of electron-withdrawing effect of the metal. The resonances of the sugar
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protons exhibit only insignificant chemical shift changes relative to native GMP. Also, the proton chemical
shifts of the methyl and the methoxide groups, 2.46 ppm and 3.78 ppm, respectively, are almost identical to
those of free trans-EE in solution [9].
The two species, M1 and M2, interchange reversibly depending on pH and chloride concentration.
The equilibrium ratio M1/M2 0.35 at pH 6.8 increases to 0.7 at pH 1.7. Addition ofNaCl to the sample also
induces a conversion of M2 to M1 indicating that the latter is the chloro complex and M2 the aqua complex.
Plots of G-H8 chemical shifts vs. pH for M1 and M2 are shown in Figure 3. The pK, at about 8.5 corresponds
to guanine N1 deprotonation. The absence of change in chemical shift at pH < 3 is clearly diagnostic for G-
N7 platination. The change of chemical shift at 5.8 corresponds to the influence of phosphate
(de)protonation.
Table 1. H NMR chemical shifts (ppm) for GMP and trans-EE platinated adducts. Reference: HDO signal at
4.76 ppm, 298 K, pH in parentheses.
6 GMP (7,1) M1 (4.8) M1 (6.8) M2 (4.8) M2 (6.8)
(ppm)
H8 8.17 8.55 8.63 8.58 8.57
HI’ 5.91 6.01 5.96 6.02 5.94
H2’ --" 4.65 5.96 4.60 5.94
H3’ 4.46 4.47 4.46 4.46 4.45
H4’ 4.30 4.36 4.34 4.37 4.33
H5’ 3.98 4.27 4’07 4.32 4.05
H5" 3.98 4.15 4.09 4.15 4.03
,NH
b 7.73 7.78 7.92 7.95
OCH 3.81 3.76 3.85 3.78
CH3 2.50 2.45 2.58 2.46
a. Overlap with residual HDO at 4.7-4.8 ppm
b. NH protons are slowly exchanged in D20 during 10-20 hours.
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Figure 3. Titration curves for G-H8 of adducts M! and M2. (298 K in 90 % H20)
The 2D H ROESY spectra for both M1 and M2 show a medium size NOE crosspeak between G-H8 and
CH3 of trans-EE. A large cross peak between H8 and CMe is expected since both are cis to platinum with
respect to the C=N double bound and therefore can come very close to each other during rotation of the
ligands about the Pt -N bonds. No crosspeak corresponding to G-HS... CH30 was detected above the noise
level. A strong intra ligand crosspeak is observed between the imino proton and the methoxide group
confirming that the iminoether ligands retain the configuration also after coordination ofGMP.
Bi-functional adducts. The bifunctional adducts M3 and M4 were characterised by H and tSN NMR
spectroscopy. The 2:1 ratio ofGMP to trans-EE ratio was confirmed by integration of H8 and CH3 (1:3 peak
intensity). The G-H8 proton chemical shifts for the two isomers are almost identical to those of the M1 and
M2 adducts. The main difference between the spectra ofM3 and M4 is that the methyl and methoxide groups
give rise to one set of signals for M3 but two sets for M4 (Figure 4 a, b).
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Figure 4. Selected regions of the ROESY spectrum of the bifunctional GMP/trans-EE adducts showing
contacts between G-H8 and the methyl and methoxide groups. The intra E-iminoether ligand cross peaks
involving OMe and N-H are also apparent. (a) M3, (b) M4
The ROESY spectrum of M3 shows two distinct crosspeaks involving H8, one strong to the methyl
group and one less intense to the methoxide group. In addition a strong intra-ligand crosspeak is observed
between the methoxide group and the imino proton. In M4 the two partly overlapping methyl signals are both
coupled to H8 while the crosspeak between OMe and NH is much greater for the isomerized iminoether (Z
configuration) than for the non isomerized one (E configuration)
SN NMR is a sensitive probe for detecting specific nitrogen binding sites on nucleobases. The use of
H-detected H-15N HMQC spectroscopy greatly enhances the sensitivity of natural abundance SN
spectroscopy. The SN resonances ofN7 and N9 are easily observed through multi-bond scalar coupling with
G-H8. A cross peak between N9 and the anomeric proton HI’ confirms the assignments. For the trans-
EE/GMP M3 complex the N7 signal is shifted to -238.4 ppm (97,5 ppm upfield that of free GMP), while N9
exhibits a minor shift to -202.9 ppm (4.3 ppm downfield that of free GMP). The large upfield shift induced
by platination is comparable to similar shifts observed for protonation of purine nitrogens (-70 ppm).
The AMP adduct. The trans-EE binding to AMP follows the same pattern as that observed_for GMP. A-H8 is
shifted 0.4 ppm downfield while A-H2 is not affected. H-SN HMQC spectroscopy of platinated AMP (M l)
shows significant upfield shift ofN7 (-247.7 ppm as compared to a free AMP N7 value of-150.8 ppm) while
N3 and N9 are only shifted downfield by about 10 ppm. This shift confirms the N7 binding ofAMP in trans-
EE adducts, of M1 at pH 4, N1 is partly protonated, therefore, the N1 signal shifts to high field by 22.3 ppm.
ROESY spectra show the AMP adduct to have a relationship to the iminoether ligand similar to GMP. A
medium sized ROESY crosspeak is observed for the A-H8 CH3 contact. Another very weak crosspeak is
observed for the A-H8 CH30 contact. In addition, the anomeric proton has weak contacts to the methyl
group.
Molecular modeling. In the molecular modeling approach using the BIOSYM software [14] for AMBER-
minimized energies the trans-EE complex was fixed in the geometry adopted in the solid state [9] except for
the methyl groups which were replaced by pseudoatoms calculated from averaging the hydrogen X-ray
coordinates. The two iminoether ligands are not coplanar in the X-ray structure but are twisted 35 to relieve
steric crowding of the methyl groups. In the calculation the configuration of the iminoether ligands were
fixed but allowed to rotate freely about the Pt-NH bonds. Also the GMP ligand was allowed to rotate freely
around the Pt-N7 bond while keeping the square-planar geometry fixed. Both the monofunctional and the
bifunctional models were subjected to energy minimization.
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Figure 5.1H-15N correlation NMR spectrum at 280 K. (a) AMP, pH 7, (b) trans-EE adduct M1, pH 4.
No symmetry constraints were applied to the relative positions of the chemically equivalent GMP ligands.
The computational details are given in ref. [8]. One may add that most probably there exixts a distribution of
several conformers. However, the NMR spectra were recorded at a temperature at which the signals from
different conformers are not resolved. A stereo-view of the refined molecular model is shown in Figure 6.
Inter and intra through-space H-H contacts are in qualitative agreement with the NMR data. The H8...CH3
distance of 3.47 3.70 A is in agreement with a relatively strong cross peak while the H8...CH30 distance of
4.49-4.93 A gives a comparatively weak cross peak.
DISCUSSION
Previously we have reported on the NMR structure of an oligonucleotide duplex platinated by trans-
EE at a guanine N7 site [8]. Only the major monofunctional adduct was structurally characterized, however,
two minor species were also present as evidenced by HPLC analysis. In this context it is of interest to explore
the relation between monofunctional vs bifunctional adduct formation which is closely related to the ability to
engage in inter and intra strand cross-linking reactions. Other trans-Pt complexes with bulky ligands, e.g.
pyridine, have been reported to have considerable enhanced ability to form interstrand cross-links over both
its cis isomer and the NH3 complexes [15]. This finding is contrary to the situation for DNA incubated with
trans-EE for 48 hr at 37 C in 10 mM NaCIO4 which was shown to produce only marginal amounts of
interstrand cross links [16]. Bierback and Farell [17] also showed that this reaction is drastically slowed (t/2
17 h, T 310 K) when one of the ammine ligands was replaced by quinoline. This latter compound exhibits
the same tendency as trans-EE to form long-lived monofunctional adducts on DNA, clearly different from
the behavior of trans-DDP.
174Metal Based Drugs Vol. 7, No. 4, 2000
Figure 6. Stereoview ofthe energy minimized molecular model of the bifunctional GMP/trans-EE adducts.
Comparison of reaction rates for trans-EE platination of mononucleotides and oligonucleotides
indicates that the trans-EE platination of the G-residue in the single strand oligonucleotide d(CCTCGTCTC)
proceeds at about the same rate as for the mononucleotide (Figure 7) [8]. For double helical DNA the
geometric restraints may drastically reduce the trans-EE platination rate.
C
o
n
c
(%)
100
8O
0
0 8 12 16 20 24
Time (h)
Figure 7. Species distribution curves for trans-EE platination ofd(CCTCGCTCTC):
(,) Major adduct (IM), () and (’) Minor adducts, (3 non-platinated oligonucleotide.
pH 2.5, no salt, at room temperature in H20. (From ref. [8]).
The difference between the GMP adducts M1 and M2 is deduced from monitoring the equilibrium as a
function of pH and addition of NaCI. Most likely M1 represents the GMP chloro complex and M2 the
corresponding solvato species. From the ROESY spectra it is evident that, in both M1 and M2, there are
strong crosspeaks between H8 of GMP and the C-Me groups of the iminoether ligands which come very
close during rotation of the ligands about the Pt-N bonds.
With excess GMP (4:1) the initially formed monofunctional adducts are converted to bifunctional
trans-EE(GMP): adducts (M3 and M4). The transition is quite slow and takes approximately 15 days to be
completed at 298 K and pH 6.8. The retention time for M3 and M4 are surprisingly close to the retention time
for the monofunctional adducts. The M3 bifunctional adduct has preserved the configuration of the
iminoether ligand (E) while in the M4 bifunctional adduct one iminoether ligand has isomerized to the Z
configuration. The concentration of the M4 isomer is initially only 1/5 of M3, however, after two months the
ratio has increased to approximately 1"1. This implies that M4 has similar stability to that of M3. This is a
rather unexpected result since in the starting dichloro species the isomer with both iminoether ligands in the E
configuration is far more stable than any other isomer. Therefore it appears that the ancillary ligands (the
purine bases in this case) are able to influence the thermodynamic stability of the iminoether configurations.
Similar geometry conversion processes were found in nucleoside-trans-EE adducts (unpublished results).
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